TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation

JCI Insight. 2021 Dec 8;6(23):e149276. doi: 10.1172/jci.insight.149276.

Abstract

Tristetraprolin (TTP), an important immunosuppressive protein regulating mRNA decay through recognition of the AU-rich elements (AREs) within the 3'-UTRs of mRNAs, participates in the pathogenesis of liver diseases. However, whether TTP regulates mRNA stability through other mechanisms remains poorly understood. Here, we report that TTP was upregulated in acute liver failure (ALF), resulting in decreased mRNA stabilities of CCL2 and CCL5 through promotion of N6-methyladenosine (m6A) mRNA methylation. Overexpression of TTP could markedly ameliorate hepatic injury in vivo. TTP regulated the mRNA stabilization of CCL2 and CCL5. Interestingly, increased m6A methylation in CCL2 and CCL5 mRNAs promoted TTP-mediated RNA destabilization. Moreover, induction of TTP upregulated expression levels of WT1 associated protein, methyltransferase like 14, and YT521-B homology N6-methyladenosine RNA binding protein 2, which encode enzymes regulating m6A methylation, resulting in a global increase of m6A methylation and amelioration of liver injury due to enhanced degradation of CCL2 and CCL5. These findings suggest a potentially novel mechanism by which TTP modulates mRNA stabilities of CCL2 and CCL5 through m6A RNA methylation, which is involved in the pathogenesis of ALF.

Keywords: Chemokines; Hepatitis; Hepatology; Inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokine CCL2 / metabolism*
  • Chemokine CCL5 / metabolism*
  • Humans
  • Liver Failure, Acute / drug therapy*
  • Methylation / drug effects*
  • Mice
  • RNA-Binding Proteins / drug effects*
  • Tristetraprolin / pharmacology
  • Tristetraprolin / therapeutic use*

Substances

  • Chemokine CCL2
  • Chemokine CCL5
  • RNA-Binding Proteins
  • Tristetraprolin